AVALO THERAPEUTICS, INC. (AVTX) Operating margin 2016–2025
AVALO THERAPEUTICS, INC. (AVTX) operating margin by fiscal year — reported operating income divided by reported revenue.
-123601.7%FY2025 · since FY2016: -1394.6% → -123601.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -123601.7% | -108066.1 pp |
| FY2024 | -15535.6% | -14114.0 pp |
| FY2023 | -1421.6% | -1214.2 pp |
| FY2022 | -207.4% | +1314.2 pp |
| FY2021 | -1521.6% | -434.2 pp |
| FY2020 | -1087.4% | -848.3 pp |
| FY2019 | -239.1% | +264.3 pp |
| FY2018 | -503.4% | -553.3 pp |
| FY2017 | 49.9% | +1444.6 pp |
| FY2016 | -1394.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More AVTX financial trends
AVTX RevenueAVTX Net incomeAVTX Net marginAVTX Gross profitAVTX Gross marginAVTX Operating incomeAVTX Operating cash flowAVTX Free cash flowAVTX Capital expendituresAVTX Return on equityAVTX Stock buybacksAVTX Dividends paidAVTX Total assetsAVTX Total liabilitiesAVTX Shareholders’ equityAVTX overview →